AstraZeneca shareholders to change their tune when money rolls in

 

Jim Armitage
Thursday 08 May 2014 08:08
Comments

Outlook Big shareholders in AstraZeneca have been less than effusive about the bid.

Some, like Aberdeen's Martin Gilbert, express reservations about the potential long-term impact on Britain's science base. Others, like Neil Woodford, fret about the effect on the combined companies' value a few years hence, saying they prefer the current AstraZeneca management to be left alone. More still, like Swedish giant Investor AB, simply think it undervalues the business.

But the big shareholders' trading patterns suggest most are licking their collective lips for the inevitable moment Pfizer significantly ups its offer. That's why they've been spending billions of pounds in recent days and weeks increasing their stakes in AstraZeneca.

A quick squint at the share register shows Mr Gilbert's own fund managers seem less squeamish than him about the deal, pumping up Aberdeen's stake last week by £511m. BlackRock and Axa likewise have been big buyers. But wiliest money-runner so far has to be JPMorgan Chase, which bought five million AstraZeneca shares in March, bringing its holdings up to nearly 14 million and giving it a paper profit of nearly £50m.

When a bid comes in north of £55 a share, expect investors' protesting voices quietly to disappear.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Please enter a valid email
Please enter a valid email
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Please enter your first name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
Please enter your last name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
You must be over 18 years old to register
You must be over 18 years old to register
Opt-out-policy
You can opt-out at any time by signing in to your account to manage your preferences. Each email has a link to unsubscribe.

By clicking ‘Create my account’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Join our new commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in